Probi Digestis® to be launched on new markets in Asia

Probi AB, a leading probiotic research and development company from Sweden and
DKSH, the leading Market Expansion Services provider with a focus on Asia,
signed an agreement for the launch of Probi Digestis® in Hong Kong and Macau.

Probi and DKSH have signed a long-term agreement for the branding and launch of
Probi’s gastrointestinal health product Probi Digestis®, based on Lactobacillus
plantarum 299v, Probi’s clinically documented probiotic strain. The agreement is
an expansion of the agreement signed in 2013 between Probi and BiO-LiFE, a
Malaysian subsidary of DKSH.

The product will be marketed in a co-branded solution with BiO-LiFE and Probi
Digestis® and will be positioned against Irritable Bowel Syndrom (IBS) symptom’s
like abdominal pain, bloating, constipation and flatulence. DKSH will market,
sell and distribute the product in both medical channels such as clinics and
hospitals as well as in pharmacies in Hong Kong and Macau.

“DKSH is an excellent partner in the growing Asian market and we are happy to
step by step expand the collaboration we initiated with DKSH in 2013 around
Probi´s clinically proven probiotic products,” says Peter Nählstedt, CEO, Probi.

"Following the launch of the probiotic product in Malaysia in 2013, we have been
enjoying a very strong relationship with Probi AB. With the growth potential in
dietary supplements for both Hong Kong and Macau, we are confident to
successfully launch Probi Digestis® in these two markets," said Richard
Holloway, Vice President, Business Unit Healthcare, DKSH Hong Kong.

To further strengthen its presence in Asia Pacific, Probi has expanded its
Marketing and Sales organisation with a regional director based in Singapore.
“By having a Probi employee working on a day-to-day basis in Asia we will be
able to give our partners strong support and intensify business developement
activities. This is the first step in the expansion and globalisation of Probi´s
Marketing and Sales team ,” says Peter Nählstedt, CEO, Probi.

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e
-mail: peter.nahlstedt@probi.se

Niklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile
+46 705 38 88 64, e-mail: niklas.bjarum@probi.se

ABOUT
PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. In 2014, Probi had sales of MSEK 135. The Probi share is listed on
NASDAQ OMX Stockholm, Small Cap. Probi has about 3,000 shareholders. Read more
at www.probi.se

ABOUT DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. As
the term "Market Expansion Services" suggests, DKSH helps other companies and
brands to grow their business in new or existing markets. Publicly listed on the
SIX Swiss Exchange since March 2012, DKSH is a global company headquartered in
Zurich. With 735 business locations in 35 countries – 710 of them in Asia – and
27,200 specialized staff, DKSH generated net sales of CHF 9.6 billion in 2013.

DKSH Business Unit Healthcare is the leading Market Expansion Services provider
for healthcare companies seeking to grow their business in Asia. Custom-made
offerings comprise registration and market entry studies as well as importation,
customs clearance, marketing and sales to physical distribution, invoicing and
cash collection. Products available through DKSH Healthcare include
pharmaceuticals, consumer health, over-the-counter (OTC), as well as medical
devices. With 150 business locations in 14 countries and around 9,050
specialized staff, Business Unit Healthcare serves over 160,000 customers and
generated net sales of around CHF 4.3 billion in 2013.